Browsing Tag
San Diego
64 posts
Aspen Neuroscience (ASPE) prices $140.6m IPO at $15 as Parkinson’s therapy enters pivotal development phase
Aspen Neuroscience has priced its Nasdaq initial public offering at $15 per share, the bottom of its proposed range, as it prepares to advance the investigational Parkinson's disease cell therapy sasineprocel into Phase 3 testing. The financing extends the company's expected operating runway into the second half of 2028, but its clinical programme remains expensive, and the company expects to require additional capital before development is complete.
LENZ Therapeutics (NASDAQ: LENZ) cuts 75% of jobs after VIZZ Q3 sales reach $2.6m
LENZ Therapeutics is cutting three-quarters of its workforce and changing CEOs despite accelerating VIZZ prescriptions, betting that a much smaller organisation can market its new presbyopia drug more efficiently.
Mesa Labs is saving $9.3m but reinvesting $4.3m. Where is the money moving?
Mesa Laboratories is eliminating approximately 40 positions while targeting $9.3 million of annualised cost savings, but plans to reinvest $4.3 million into growth priorities. The restructuring narrows Clinical Genomics around higher-utilisation customers and redirects resources toward Asia, calibration and other higher-return businesses.
Supio wants AI to call insurers and chase medical records. Is legal automation entering a new phase?
Supio’s Case Communications connects calls, texts, emails and faxes directly to legal case context, extending its AI agents beyond document analysis into external case coordination and raising the stakes around oversight, security and professional accountability.
Nayax shares jump 13% on $350 million IPS Group deal as smart parking opportunity expands
Nayax is buying IPS Group for $350M, adding $90M of smart-parking revenue and expanding its cashless market opportunity by $85B.
ResMed’s FY27 guidance reset tests investor confidence in sleep-apnea device growth
ResMed’s FY27 guidance reset pressured RMD despite strong cash flow. Read how Astral, GLP-1 drugs, MatrixCare and buybacks shape the medtech story.
ResMed (ASX: RMD) drops 8% as Astral recall clouds FY27 outlook
ResMed fell 8% as FY27 sales guidance missed expectations. Astral recall costs and slower growth now test the ASX: RMD valuation.
Why Capstone Energy+’s Scripps Mercy project matters more than its 2 MW capacity suggests
The Scripps Mercy Hospital installation gives Capstone Energy+ a high-value healthcare reference, but commissioning, verified economics and repeat orders will determine its commercial significance.
Everest Medicines closes $1.14bn Travere deal for rare kidney disease drug
Everest Medicines closes its $1.14 billion Travere deal for civorebrutinib. Read how the BTK licence reshapes 1952.HK, TVTX and rare kidney strategy.
Why ABB’s NASCAR microgrid showcase could matter beyond motorsports
Find out how ABB’s NASCAR Grid Control could shape ABBN stock sentiment, microgrid demand and temporary event power strategy today!